The cost of chemotherapy administration: a systematic review and meta-analysis.
Cancer
Chemotherapy
Cost
Healthcare systems
Medico-economic
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
05
04
2020
accepted:
25
02
2021
pubmed:
10
3
2021
medline:
18
9
2021
entrez:
9
3
2021
Statut:
ppublish
Résumé
Cancer treatment is a significant driver of healthcare costs worldwide, however, the economic impact of treating patients with anti-neoplastic agents is poorly elucidated. We conducted a systematic review and meta-analysis to estimate the direct costs associated with administering intravenous chemotherapy in an outpatient setting. We systematically searched four databases from 2010 to present and extracted hourly administration costs and the respective components of each estimate. Separate analyses were conducted of Canadian and United States (US) studies, respectively, to address a priori hypotheses regarding heterogeneity amongst estimates. The Drummond checklist was used to assess risk-of-bias. Data were summarized using medians with interquartile ranges and five outliers were identified; costs were presented in 2019 USD. Forty-four studies were analyzed, including sub-analyses of 19 US and seven Canadian studies. 26/44 studies were of moderate-high quality. When components of administration cost were evaluated, physician costs were reported most frequently (24 studies), followed by lab tests (13) and overhead costs (9). The median estimate (excluding outliers) was $142/hour (IQR = $103-166). The median administration cost in the US was $149/hour (IQR = $118-158), and was $128/hour (IQR = $102-137) in Canada. There is currently a paucity of literature addressing the costs of chemotherapy administration, and existing studies utilize a patchwork of reporting methodologies which renders direct comparison challenging. Our results demonstrate that the cost of administering chemotherapy is approximately $125-150/hour, globally. This value is dependent upon the region of analysis, inclusiveness of cost subcomponents as well as the methodology used to estimate unit prices, as described here.
Identifiants
pubmed: 33687618
doi: 10.1007/s10198-021-01278-0
pii: 10.1007/s10198-021-01278-0
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-620Références
International agency for research on cancer: all cancers (Fact Sheet) [cited 2019 Jun 21] Available from: http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf (2019)
Albaba, H., Lim, C., Leighl, N.B.: Economic considerations in the use of novel targeted therapies for lung cancer: review of current literature. Pharmacoeconomics 35, 1195–1209 (2017)
pubmed: 28861770
Nabhan, C., Feinberg, B.A.: Value-based calculators in cancer: current state and challenges. J Oncol Pract 13, 499–506 (2017)
pubmed: 28617618
Moher, D., Liberati, A., Tetzlaff, J., et al.: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097 (2009)
pubmed: 2707599
pmcid: 2707599
Levy, J.: Systematic review and meta-analysis protocol (Version 1): the cost of chemotherapy administration: a systematic review and meta-analysis (2018) PROSPERO 2018 CRD42018103166 Available from https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018103166
DistillerSR. Evidence Partners (2019, Evidence Partners, Ottawa, Canada). Available from https://v2dis-prod.evidencepartners.com/
US inflation calculator. Coin news media group, LLC (2019). Available from https://www.usinflationcalculator.com/
XE currency converter. XE (2019). Available from https://www.xe.com/currencyconverter/
Drummond, M., et al.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford (1997)
Drummond, M.F., Jefferson, T.O.: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. BMJ 313, 275–283 (1996)
pubmed: 8704542
pmcid: 2351717
Saxton, A.T., Poenaru, D., Ozgediz, D., et al.: Economic analysis of children’s surgical care in low- and middle-income countries: a systematic review and analysis. PLoS ONE 11, e0165480 (2016)
pubmed: 27792792
pmcid: 5085034
Abbott, D.E., Merkow, R.P., Cantor, S.B., et al.: Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol 19, 3659–3667 (2012)
pubmed: 22965567
Abbott, D.E., Tzeng, C.-W.D., Merkow, R.P., et al.: the cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 20(Suppl 3), S500-508 (2013)
pubmed: 23397153
Amdahl, J., Manson, S.C., Isbell, R., et al.: Cost-effectiveness of oazopanib in advanced soft tissue sarcoma in the united kingdom. Sarcoma 2014, 481071 (2014)
pubmed: 25024640
pmcid: 4082932
Awan, F., Kochuparambil, S.T., Falconer, D.E., et al.: Comparable efficacy and lower cost of PBSC mobilization with Intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 48, 1279–1284 (2013)
pubmed: 23584435
Babashov, V., Begen, M.A., Mangel, J., et al.: Economic evaluation of brentuximab vedotin for persistent hodgkin lymphoma. Curr Oncol 24, e6–e14 (2017)
pubmed: 28270727
pmcid: 5330640
Bernard, L.M., Verma, S., Thompson, M.F., et al.: A Canadian economic analysis of U.S. Oncology adjuvant trial 9735. Curr Oncol 18, 67–75 (2011)
pubmed: 21505597
pmcid: 3070705
Chen, Q., Ayer, T., Nastoupil, L.J., et al.: Comparing the cost-effectiveness of Rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health 18, 189–197 (2015)
pubmed: 25773554
pmcid: 4363091
Dranitsaris, G., Coleman, R., Gradishar, W.: Nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with Metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 119, 717–724 (2010)
pubmed: 19495958
Duong, M., Wright, E., Yin, L., et al.: The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada. Curr Oncol 23, e461–e467 (2016)
pubmed: 27803606
pmcid: 5081018
Durkee, B.Y., Qian, Y., Pollom, E.L., et al.: Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 34, 902–909 (2016)
pubmed: 26351332
Espinosa Bosch, M., Asensi Diez, R., García Agudo, S., et al.: Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. Farm Hosp 40, 316–327 (2016)
pubmed: 27571499
Farolfi, A., Silimbani, P., Gallegati, D., et al.: Resource utilization and cost saving analysis of subcutaneous versus intravenous Trastuzumab in early breast cancer patients. Oncotarget 8, 81343–81349 (2017)
pubmed: 29113393
pmcid: 5655288
Flannery, K., Drea, E., Hudspeth, L., et al.: budgetary impact of cabazitaxel use after docetaxel treatment for metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm 23, 416–426 (2017)
pubmed: 28345444
Gharaibeh, M., McBride, A., Bootman, J.L., et al.: Economic evaluation for the US of Nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ 20, 345–352 (2017)
pubmed: 27919186
Goldstein, D.A., Chen, Q., Ayer, T., et al.: Cost effectiveness analysis of pharmacokinetically-guided 5-Fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 13, 219–225 (2014)
pubmed: 25306485
Goldstein, D.A., Chen, Q., Ayer, T., et al.: First- and second-line Bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 33, 1112–1118 (2015)
pubmed: 25691669
pmcid: 4881313
Goldstein, D.A., Chen, Q., Ayer, T., et al.: Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol 1, 1293–1300 (2015)
pubmed: 26313558
Goulart, B., Ramsey, S.: A trial-based assessment of the cost-utility of Bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14, 836–845 (2011)
pubmed: 21914503
Haywood, P., de Raad, J., van Gool, K., et al.: Chemotherapy administration: modelling the costs of alternative protocols. Pharmacoeconomics 30, 1173–1186 (2012)
pubmed: 23148697
He, J., Wen, F., Yin, X., et al.: Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer. Anticancer Drugs 24, 754–758 (2013)
pubmed: 23629479
Hornberger, J., Chien, R., Friedmann, M., et al.: Cost-effectiveness of Rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma 53, 2371–2377 (2012)
pubmed: 22591119
Hornberger, J., Hirsch, F.R., Li, Q., et al.: Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. Lung Cancer 88, 223–230 (2015)
pubmed: 25804732
Howard, D.R., Munir, T., McParland, L., et al.: Clinical effectiveness and cost-effectiveness results from the randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the attenuated dose rituximab with chemotherapy in chronic lymphocytic leukaemia (ARCTIC) trial. Health Technol Assess 21, 1–374 (2017)
pubmed: 28628003
pmcid: 5494514
Hui, L., von Keudell, G., Wang, R., et al.: Cost-effectiveness analysis of consolidation with Brentuximab Vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123, 3763–3771 (2017)
pubmed: 28640385
pmcid: 5610636
Joerger, M., Matter-Walstra, K., Früh, M., et al.: Addition of Cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 22, 567–574 (2011)
pubmed: 20843984
Kumar, G., Woods, B., Hess, L.M., et al.: Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer 89, 294–300 (2015)
pubmed: 26122345
Lachaine, J., Mathurin, K., Barakat, S., et al.: Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Eur J Haematol 95, 218–229 (2015)
pubmed: 25354894
Lachaine, J., Mathurin, K., Barakat, S., et al.: Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. Hematol Oncol 33, 229–238 (2015)
pubmed: 25424534
Lee, E.-K., Revil, C., Ngoh, C.A., et al.: Clinical and cost effectiveness of Bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin Ther 34, 1408–1419 (2012)
pubmed: 22657254
Lesnock, J.L., Farris, C., Krivak, T.C., et al.: Consolidation Paclitaxel is more cost-effective than Bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol 122, 473–478 (2011)
pubmed: 21665250
pmcid: 3152641
Mihajlović, J., Bax, P., van Breugel, E., et al.: Microcosting study of rituximab subcutaneous injection versus intravenous infusion. Clin Ther 39, 1221-1232.e4 (2017)
pubmed: 28579210
Nam, J., Milenkovski, R., Yunger, S., et al.: Economic evaluation of Rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. J Med Econ 21, 47–59 (2018)
pubmed: 28837377
Pettersson, K., Carlsson, G., Holmberg, C., et al.: Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden: a clinical practice model approach. Acta Oncol 51, 840–848 (2012)
pubmed: 22937953
Phippen, N.T., Leath, C.A., Havrilesky, L.J., et al.: Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? Gynecol Oncol 136, 43–47 (2015)
pubmed: 25448456
Riesco-Martínez, M.C., Berry, S.R., Ko, Y.-J., et al.: Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type kras unresectable metastatic colorectal cancer. J Oncol Pract 12, e710-723 (2016)
pubmed: 27143148
Roth, J.A., Carlson, J.J.: Cost-effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine monotherapy in advanced biliary tract cancer. J Gastrointest Cancer 43, 215–223 (2012)
pubmed: 21234709
Schremser, K., Rogowski, W.H., Adler-Reichel, S., et al.: Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33, 1215–1228 (2015)
pubmed: 26081300
van Gils, C.W.M., de Groot, S., Tan, S.S., et al.: Real-world resource use and costs of adjuvant treatment for stage III colon cancer. Eur J Cancer Care (Engl) 24, 321–332 (2015)
Vergnenegre, A., Corre, R., Berard, H., et al.: Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an Economic, randomized, prospective, multicenter phase III trial comparing Docetaxel and Pemetrexed: the GFPC 05–06 study. J Thorac Oncol 6, 161–168 (2011)
pubmed: 21150465
Ward, M.C., Shah, C., Adelstein, D.J., et al.: Cost-effectiveness of Nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol 74, 49–55 (2017)
pubmed: 29103751
Woods, B., Hawkins, N., Dunlop, W., et al.: Bendamustine versus Chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 15, 759–770 (2012)
pubmed: 22867787
Zhou, J., Zhao, R., Wen, F., et al.: Cost-effectiveness analysis of Gemcitabine, S-1 and Gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Med Oncol 32, 121 (2015)
pubmed: 25788034
Zhou, K.R., Cheng, A., Ng, W.T., et al.: Cost minimization analysis of Capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. J Med Econ 20, 541–548 (2017)
pubmed: 28277030
Zhou, Z.-Y., Mutebi, A., Han, S., et al.: Cost-effectiveness of Ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. J Med Econ 21, 577–586 (2018)
pubmed: 29458286
CPT 96413: Under injection and intravenous infusion chemotherapy and other highly complex drug or highly complex biologic agent administration [Available from, https://coder.aapc.com/cpt-codes/96413 ] (2019)
Ministry of health and long term care: Schedule of benefits physician services under the health insurance act [cited 2019 Jun 18] [Available from, http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20200306.pdf ] (2005)
Suh, D.-C., Powers, C.A., Barone, J.A., et al.: Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: a microcosting study. Res Social Adm Pharm 6, 246–256 (2010)
pubmed: 20813337
pmcid: 5292979
Centers for medicare and medicaid services: National physician fee schedule relative value file calendar year 2011 [cited 2019 Jun 18] Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Relative-Value-Files-Items/CMS1241243.html (2010)
Centers for medicare and medicaid services: medicare program: Payment policies under the physician fee schedule, five-year review of work relative value units, clinical laboratory fee schedule: signature on requisition, and other revisions to part B for CY 2012 [cited 2019 Jun 18] Available from: https://www.federalregister.gov/documents/2011/11/28/2011-28597/medicare-program-payment-policies-under-the-physician-fee-schedule-five-year-review-of-work-relative (2012)
Department of health: NHS reference costs 2006–07 [cited 2019 August 14] Available from: https://webarchive.nationalarchives.gov.uk/20130104223439/http://www.dh.gov.uk/en/Publicationsandstatistics/PublicationsPolicyAndGuidance/DH_082571 (2008)
Lavis, J.N., Hammill, A.C.,: Governance arrangements., in Ontario’s health system: key insights for engaged citizens, professionals and policymakers. Hamilton, McMaster Health Forum 45–71 (2016)
McGowan, J., Sampson, M., Salzwedel, D.M., Cogo, E., Foerster, V., Lefebvre, C.: PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75, 40–46 (2016)
pubmed: 27005575